How emerging biotechs can enter the Chinese market and prosper
Small and emerging biotechs in the United States and Europe have long been wary of trying to enter the Chinese market, despite its vast potential. They’ve shied away due to changing regulatory and reimbursement policies, unreliable intellectual property protections, and fear that the Chinese government may favor domestic firms. But things have changed, and companies don’t need to be hesitant anymore.
Since 2015, a slew of economic and regulatory reforms have improved the Chinese market dynamics for foreign companies. In 2018, the Chinese State Council eliminated tariffs (of 6% to 10%) on all imported cancer drugs and slashed the value-added tax on them from 17% to 3%. In 2020, 28 new drugs from nondomestic companies were approved by the National Medical Products Administration (NMPA), faster and more dependably than before. In May 2021, China was reelected for a three-year term to the management committee of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, further aligning it with international regulatory standards.
Large international pharma companies often include China because of its market size, and many put it near the top of the list when sequencing global marketing submissions. But how can small and emerging foreign companies with limited resources gain a foothold in the Chinese market? Here are five approaches that help.
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
New Real World Evidence leader in Asia/Pacific returns to Parexel with lessons learned from China adventure
Jan 13, 2023
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Podcast
Funding Biotech Innovation: How to Attract Investors
Jan 18, 2022
Video
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
New Real World Evidence leader in Asia/Pacific returns to Parexel with lessons learned from China adventure
Jan 13, 2023
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Podcast
Funding Biotech Innovation: How to Attract Investors
Jan 18, 2022
Video
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022